Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity
Copyright © 2024 Elsevier Inc. All rights reserved..
The SARS-CoV-2 Omicron variant, which was classified as a variant of concern (VOC) by the World Health Organization on 26 November 2021, has attracted worldwide attention for its high transmissibility and immune evasion ability. The existing COVID-19 vaccine has been shown to be less effective in preventing Omicron variant infection and symptomatic infection, which brings new challenges to vaccine development and application. Here, we evaluated the immunogenicity and safety of an Omicron variant COVID-19 inactivated vaccine containing aluminum and CpG adjuvants in a variety of animal models. The results showed that the vaccine candidate could induce high levels of neutralizing antibodies against the Omicron variant virus and binding antibodies, and significantly promoted cellular immune response. Meanwhile, the vaccine candidate was safe. Therefore, it provided more foundation for the development of aluminum and CpG as a combination adjuvant in human vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:594 |
|---|---|
| Enthalten in: |
Virology - 594(2024) vom: 09. Apr., Seite 110050 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Xiaotong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.virol.2024.110050 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369687752 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369687752 | ||
| 003 | DE-627 | ||
| 005 | 20240409232623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.virol.2024.110050 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM369687752 | ||
| 035 | |a (NLM)38479071 | ||
| 035 | |a (PII)S0042-6822(24)00071-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Xiaotong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a The SARS-CoV-2 Omicron variant, which was classified as a variant of concern (VOC) by the World Health Organization on 26 November 2021, has attracted worldwide attention for its high transmissibility and immune evasion ability. The existing COVID-19 vaccine has been shown to be less effective in preventing Omicron variant infection and symptomatic infection, which brings new challenges to vaccine development and application. Here, we evaluated the immunogenicity and safety of an Omicron variant COVID-19 inactivated vaccine containing aluminum and CpG adjuvants in a variety of animal models. The results showed that the vaccine candidate could induce high levels of neutralizing antibodies against the Omicron variant virus and binding antibodies, and significantly promoted cellular immune response. Meanwhile, the vaccine candidate was safe. Therefore, it provided more foundation for the development of aluminum and CpG as a combination adjuvant in human vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adjuvant | |
| 650 | 4 | |a CpG | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Aluminum |2 NLM | |
| 650 | 7 | |a CPD4NFA903 |2 NLM | |
| 650 | 7 | |a aluminum sulfate |2 NLM | |
| 650 | 7 | |a 34S289N54E |2 NLM | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Alum Compounds |2 NLM | |
| 700 | 1 | |a Yang, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yuxiu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yadan |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Guangying |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Weidong |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Zhuangzhuang |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Xiaofei |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yancen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hongqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Shaoting |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ankang |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Shouzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuntao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology |d 1955 |g 594(2024) vom: 09. Apr., Seite 110050 |w (DE-627)NLM000011347 |x 1096-0341 |7 nnns |
| 773 | 1 | 8 | |g volume:594 |g year:2024 |g day:09 |g month:04 |g pages:110050 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.virol.2024.110050 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 594 |j 2024 |b 09 |c 04 |h 110050 | ||